» Articles » PMID: 34071187

Cortical Excitability Across the ALS Clinical Motor Phenotypes

Overview
Journal Brain Sci
Publisher MDPI
Date 2021 Jun 2
PMID 34071187
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Amyotrophic lateral sclerosis (ALS) is characterized by its marked clinical heterogeneity. Although the coexistence of upper and lower motor neuron signs is a common clinical feature for most patients, there is a wide range of atypical motor presentations and clinical trajectories, implying a heterogeneity of underlying pathogenic mechanisms. Corticomotoneuronal dysfunction is increasingly postulated as the harbinger of clinical disease, and neurophysiological exploration of the motor cortex in vivo using transcranial magnetic stimulation (TMS) has suggested that motor cortical hyperexcitability may be a critical pathogenic factor linked to clinical features and survival. Region-specific selective vulnerability at the level of the motor cortex may drive the observed differences of clinical presentation across the ALS motor phenotypes, and thus, further understanding of phenotypic variability in relation to cortical dysfunction may serve as an important guide to underlying disease mechanisms. This review article analyses the cortical excitability profiles across the clinical motor phenotypes, as assessed using TMS, and explores this relationship to clinical patterns and survival. This understanding will remain essential to unravelling central disease pathophysiology and for the development of specific treatment targets across the ALS clinical motor phenotypes.

Citing Articles

TDP-43 pathology is sufficient to drive axon initial segment plasticity and hyperexcitability of spinal motoneurones in vivo in the TDP43-ΔNLS model of Amyotrophic Lateral Sclerosis.

Djukic S, Zhao Z, Jorgensen L, Bak A, Jensen D, Meehan C Acta Neuropathol Commun. 2025; 13(1):42.

PMID: 39994742 PMC: 11849383. DOI: 10.1186/s40478-025-01934-z.


Schwann Cells in Neuromuscular Disorders: A Spotlight on Amyotrophic Lateral Sclerosis.

Moss K, Saxena S Cells. 2025; 14(1).

PMID: 39791748 PMC: 11719703. DOI: 10.3390/cells14010047.


Amyotrophic lateral sclerosis represents corticomotoneuronal system failure.

Eisen A, Vucic S, Kiernan M Muscle Nerve. 2024; 71(4):499-511.

PMID: 39511939 PMC: 11887532. DOI: 10.1002/mus.28290.


Betz cells of the primary motor cortex.

Nolan M, Scott C, Hof P, Ansorge O J Comp Neurol. 2024; 532(1):e25567.

PMID: 38289193 PMC: 10952528. DOI: 10.1002/cne.25567.


Cytoplasmic Human TDP-43 Mislocalization Induces Widespread Dendritic Spine Loss in Mouse Upper Motor Neurons.

Dyer M, Woodhouse A, Blizzard C Brain Sci. 2021; 11(7).

PMID: 34209287 PMC: 8301870. DOI: 10.3390/brainsci11070883.

References
1.
Turner M, Kiernan M . Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. Amyotroph Lateral Scler. 2012; 13(3):245-50. DOI: 10.3109/17482968.2011.636050. View

2.
Menon P, Yiannikas C, Kiernan M, Vucic S . Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. 2019; 6(8):1373-1382. PMC: 6689694. DOI: 10.1002/acn3.50819. View

3.
Saberi S, Stauffer J, Schulte D, Ravits J . Neuropathology of Amyotrophic Lateral Sclerosis and Its Variants. Neurol Clin. 2015; 33(4):855-76. PMC: 4628785. DOI: 10.1016/j.ncl.2015.07.012. View

4.
Turner M, Hammers A, Al-Chalabi A, Shaw C, Andersen P, Brooks D . Distinct cerebral lesions in sporadic and 'D90A' SOD1 ALS: studies with [11C]flumazenil PET. Brain. 2005; 128(Pt 6):1323-9. DOI: 10.1093/brain/awh509. View

5.
Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R . Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. 2016; 6(9):e012054. PMC: 5051496. DOI: 10.1136/bmjopen-2016-012054. View